VacZine Analytics  
MarketVIEW: Acinetobacter baumannii vaccines

Published: April 2017

Acinetobacter baumannii of the Acinetobacter spp is a ubiquitous aerobic gram-negative bacillus which preferentially colonizes aquatic environments. Recently, the bacterium has become a "Priority No 1" pathogen primarily associated with hospital-acquired infections (HAIs). Patients usually affected are those critically ill having been admitted to the intensive care unit (ICU) and often receiving mechanical ventilation. In these instances A.baumannii related pneumonia can have high mortality rates of 50% or above. A.baumannii hospital infections can be difficult to treat with current antibiotics especially multidrug resistant forms MDR, XDR and PDR. In addition, such infections dramatically increase hospital length of stay (LOS) and economic cost.

This MarketVIEW product is composed of a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Acinetobacter baumannii vaccines across major Western markets to 2030. Three scenarios (LO, BASE and HI) are included based upon successive targeting of patient groups who would benefit from vaccination. A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach. An ideal Target Product Profile (TPP) is defined along with commercial model assumptions with economic pricing justification.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV070 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2017 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains